Valion Bio, Inc. (VBIO)
| Market Cap | 547.47K -88.0% |
| Revenue (ttm) | n/a |
| Net Income | -19.23M |
| EPS | -210.20 |
| Shares Out | 887.59K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 139,957 |
| Open | 0.6500 |
| Previous Close | 0.6788 |
| Day's Range | 0.6163 - 0.7019 |
| 52-Week Range | 0.6163 - 67.5000 |
| Beta | 1.80 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About VBIO
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in Apr... [Read more]
Financial Performance
Financial StatementsNews
Valion Bio announces data from NIAID, RNCP-funded safety study of Entolimod
Valion Bio (VBIO) announced final data from a National Institute of Allergy and Infectious Diseases, NIAID/Radiation and Nuclear Countermeasures Program, RNCP,-funded safety study of its lead biologic...
Valion Bio receives unsolicited acquisition interest in Velocity Bioworks
Valion Bio (VBIO) has received unsolicited acquisition inquiries from independent third parties concerning its wholly owned contract development and manufacturing organization, Velocity Bioworks. The ...
Valion Bio unveils agenda to accelerate clinical pipeline, shareholder value
Valion Bio (VBIO) shared the initial findings and priorities from Dean Zikria’s first 30 days as Interim CEO. Mr. Zikria’s strategic review has set a focused agenda built on three…
Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value
Interim CEO Dean Zikria's initial review prioritizes Entolimod and pipeline advancement, commercialization of Velocity Bioworks, and strategic opportunities to maximize the value of the Company's inte...
Valion Bio files to sell 3.95M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.95M shares of common stock. The company is not selling any…
Valion Bio Proxy statement: Proxy filing
Valion Bio filed a proxy statement on October 16, 2026, providing details for shareholder voting and corporate governance matters.
Valion Bio Registration statement: Registration filing
Valion Bio filed a registration statement on October 16, 2026, providing details about a securities offering with the SEC.
Valion, LarmorBio announces Velocity completed feasibility eval of BioScan-NMR
Valion Bio (VBIO) and LarmorBio announced that Velocity Bioworks, Valion’s wholly owned biologics contract development and manufacturing organization subsidiary, has successfully completed an initial ...
Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone
Velocity Bioworks successfully completes initial evaluation of LarmorBio's BioScan-NMR™ platform, generating data supporting the continued development of continuous, real-time, non-invasive bioprocess...
Valion Bio highlights capabilities of Velocity Bioworks
Valion Bio (VBIO) highlighted the capabilities of its wholly owned contract development and manufacturing organization, CDMO, Velocity Bioworks. Velocity Bioworks is part of Valion’s own domestic biol...
With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge
Velocity Bioworks' San Antonio facility offers process development, analytical services, and early-phase clinical drug substance manufacturing for biotechnology companies evaluating U.S.-based product...
Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers
Rising electricity demand from AI and data centers is driving plans to expand nuclear power capacity, possibly including on-site small modular reactors (SMRs)¹ Medical countermeasures need to scale al...
Valion Bio Registration statement: Registration filing
Valion Bio filed a registration statement on October 8, 2026, providing details about a securities offering with the SEC.
Valion Bio files $100M mixed securities shelf
06:06 EDT Valion Bio (VBIO) files $100M mixed securities shelf
Valion Bio outlines perspectives of new Board Chair Jensen
Valion Bio (VBIO) outlined the perspectives of its new Board Chair, Thomas Jensen, on advancing Entolimod. Entolimod is an investigational Toll-like receptor 5, TLR5, agonist being developed as a pote...
New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod
Jensen, who as CEO led Nasdaq-listed biotech Allarity Therapeutics' refocusing around a single lead asset, cites Valion's rare combination of government funding, FDA designations, human safety data an...
Valion Bio Proxy statement: Proxy filing
Valion Bio filed a proxy statement on October 2, 2026, providing details for shareholder voting and corporate governance matters.
Valion Bio, Shear Kershman formulate oral mucosal entolimod
Valion Bio (VBIO) and Shear Kershman Laboratories announced the completion of formulation work under the companies’ ongoing program to develop a novel oral mucosal formulation of Entolimod, Valion’s i...
Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity
Needle-free program creates a potential second development pathway alongside Valion's injectable Entolimod program Next study will test whether the formulation delivers measurable amounts of Entolimod...
Valion Bio appoints Dean Zikria as interim CEO, Thomas Jensen as chair
Valion Bio (VBIO) announced decisive changes to its executive leadership team and Board of Directors. These leadership transitions are intended to strengthen organizational alignment and support focus...
Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
Leadership changes strengthen alignment and execution as Company advances Entolimod and evaluates strategic, commercial and government opportunities SAN ANTONIO, TX / ACCESS Newswire / September 23, 2...
Valion Bio regains compliance with Nasdaq minimum bid price listing rule
Valion Bio (VBIO) has received formal written notification from The Nasdaq Stock Market confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing ...
Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
Nasdaq confirms compliance with continued listing standard and closes the matter SAN ANTONIO, TX / ACCESS Newswire / September 22, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) ("Valion" or the "Company) anno...
Valion Bio appoints CFO Lisa Wolf as president, COO
Valion Bio (VBIO) announced strategic changes to its management team and Board of Directors designed to accelerate execution across its clinical and commercial initiatives and position the Company for...
Valion Bio Announces Changes to Management and Board of Directors
Current CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors.